Relapsing Polychondritis: Difference between revisions
No edit summary |
mNo edit summary |
||
| Line 31: | Line 31: | ||
add text here relating to the differential diagnosis of this condition<br> | add text here relating to the differential diagnosis of this condition<br> | ||
== | == Prognosis == | ||
Most individuals with RP typically experience a variable disease course marked by intermittent episodes of inflammation. During each flare-up, the specific sites affected and the severity of involvement tend to change and are not consistent. Many patients also deal with persistent symptoms in between these acute episodes. | |||
Fortunately, with better management of RP-related complications, survival rates have significantly improved. For instance, in 1986, the 10-year survival rate was only 55%, but by 1998, it had risen to an impressive 94% at the end of 8 years. The primary causes of mortality in these individuals include lower respiratory tract infections, airway collapse, cardiac issues like valvular disease, and advanced systemic vasculitis.<ref>Sharma A, Gnanapandithan K, Sharma K, Sharma S. Relapsing polychondritis: a review. Clinical Rheumatology. 2013 Jul 26;32(11):1575–83.</ref> | |||
== References == | == References == | ||
Revision as of 08:48, 2 September 2023
Top Contributors - Pacifique Dusabeyezu, Kim Jackson and Carina Therese Magtibay
Clinically Relevant Anatomy
[edit | edit source]
Relapsing polychondritis (RP) is a rare multisystem autoimmune condition with an unknown cause. It is characterized by recurring episodes of inflammation that lead to the gradual destruction of various cartilaginous tissues in the body. This includes elastic cartilage found in the ears and nose, hyaline cartilage in peripheral joints, fibrocartilage in the spine, and cartilage in the tracheobronchial system. RP can affect structures rich in proteoglycans, such as those in the eye, heart, blood vessels, and inner ear.[1]
Etiology[edit | edit source]
The etiology of RP remains unknown so far. Studies have shown the association of both cellular immunity changes and abnormal autoantibody response in RP.
Clinical Presentation[edit | edit source]
add text here relating to the clinical presentation of the condition
Diagnostic Procedures[edit | edit source]
add text here relating to diagnostic tests for the condition
Outcome Measures[edit | edit source]
add links to outcome measures here (see Outcome Measures Database)
Management / Interventions
[edit | edit source]
add text here relating to management approaches to the condition
Differential Diagnosis
[edit | edit source]
add text here relating to the differential diagnosis of this condition
Prognosis[edit | edit source]
Most individuals with RP typically experience a variable disease course marked by intermittent episodes of inflammation. During each flare-up, the specific sites affected and the severity of involvement tend to change and are not consistent. Many patients also deal with persistent symptoms in between these acute episodes.
Fortunately, with better management of RP-related complications, survival rates have significantly improved. For instance, in 1986, the 10-year survival rate was only 55%, but by 1998, it had risen to an impressive 94% at the end of 8 years. The primary causes of mortality in these individuals include lower respiratory tract infections, airway collapse, cardiac issues like valvular disease, and advanced systemic vasculitis.[2]
